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Abstract: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with extensive
genetic and aetiological heterogeneity. While the underlying molecular mechanisms involved remain
unclear, significant progress has been facilitated by recent advances in high-throughput transcriptomic,
epigenomic and proteomic technologies. Here, we review recently published ASD proteomic data and
compare proteomic functional enrichment signatures with those of transcriptomic and epigenomic data.
We identify canonical pathways that are consistently implicated in ASD molecular data and find an
enrichment of pathways involved in mitochondrial metabolism and neurogenesis. We identify a subset
of differentially expressed proteins that are supported by ASD transcriptomic and DNA methylation
data. Furthermore, these differentially expressed proteins are enriched for disease phenotype pathways
associated with ASD aetiology. These proteins converge on protein–protein interaction networks that
regulate cell proliferation and differentiation, metabolism, and inflammation, which demonstrates a
link between canonical pathways, biological processes and the ASD phenotype. This review highlights
how proteomics can uncover potential molecular mechanisms to explain a link between mitochondrial
dysfunction and neurodevelopmental pathology.
Keywords: proteomics; transcriptomics; DNA methylation; mitochondria; metabolism; OXPHOS;
ASD; neurogenesis; gliosis; neurodevelopment
1. Introduction
Autism Spectrum Disorder (ASD) is a lifelong neurodevelopmental condition that is
characterized by heterogeneous genetic origins and a poorly understood aetiology [1]. Al-
though the heritability of ASD is undisputed, the genetic contribution of ASD is only 64.6% [2]
to 80% [3]. The genetic architecture of ASD comprises highly penetrant, rare variants, as well
as more common variants which have smaller effect sizes [4]. However, no single genetic
variant accounts for more than 1% of ASD cases [5], with more than 90% of ASD cases being
idiopathic [6]. Recent technological advances in genomics, coupled with systems biology
approaches that use functional genomic datasets, have facilitated remarkable progress in
understanding the functional convergence of the genetic loci associated with ASD [7]. How-
ever, a challenge of ASD molecular research is being able to “translate gene discovery into an
actionable understanding of ASD pathology” [8]. Transcriptomic and epigenomic approaches
are widely used to study gene regulation and expression in ASD, and these have provided
some insight into the functional changes at the molecular level. However, there have been
fewer proteomic studies in ASD, due in part to the numerous challenges of this approach.
Proteomic methodological approaches vary widely with respect to sample preparation, instru-
mentation, and protein quantification methods, all of which culminates in studies with limited
reproducibility [9]. Additionally, the lack of unified data repositories and standardised protein
identifiers make it difficult to integrate results between different studies [10]. However, as the
“undertakers of biological activities” [11], proteins directly reflect the physiological processes
underpinning disease aetiology. Therefore, proteomics is an essential tool to characterise the
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cellular mechanisms involved in ASD aetiology and to validate the changes observed in the
ASD transcriptome and epigenome.
We propose that the integration of ASD proteomic data with large scale ASD transcrip-
tomic and DNA methylation (DNAm) data may yield insight into the molecular mechanisms
of ASD. Despite the aetiological and genetic complexity of ASD, this underlying heterogeneity
is thought to converge on a limited number of biochemical pathways [12]. Integrative analyses
of disparate molecular datasets are well-suited for the identification of common functional
networks implicated in complex disorders and these networks can identify potential relation-
ships between disease mechanisms and phenotypes [13]. In this review, we collate recently
published data from independent transcriptomic, DNAm, and proteomics studies to identify
canonical pathways that are consistently implicated in ASD. Importantly, the purpose of this
review is not to combine these disparate datasets in a bioinformatic analysis. Instead, these
datasets will be functionally annotated in a uniform manner for comparison. First, we will
examine this data to identify common shared canonical pathways across different molecular
datasets. Subsequently, we will explore ASD proteomic datasets to identify differentially ex-
pressed proteins that are also implicated in the transcriptomic and DNAm data. Finally, these
proteins will be characterised with respect to enriched protein–protein interaction networks
to investigate the link between differentially expressed proteins, enriched canonical pathways
and biological processes involved in ASD aetiology.
2. Methods
This review integrated data from large-scale quantitative meta-analyses from both tran-
scriptomic and DNAm data, as well as from ASD proteomic datasets published over the
past five years. Overall, data were collated from 19 studies and meta-analyses from ASD
cohorts published between 2017 and 2021 (Table 1). The publications included six proteomic
datasets [11,14–18], eight transcriptomic studies [19–26], and five DNAm screens [26–30]. The
data collated from each study were the published list of genes or proteins found to be signifi-
cantly associated with ASD after data quality control, normalisation, processing, statistical
analyses and peer review (Supplementary Table S1). The datasets used in this review were
treated as inherently and intentionally heterogeneous given that the data were: (i) derived
from different cohorts spanning a wide range of ages and tissue types from both blood and
brain samples, (ii) generated using different molecular approaches, (iii) subject to different
data processing and quality control workflows, and (iv) filtered using different methods to
determine statistical significance. Rather than combine the raw datasets in a bioinformatic
analysis, the final published lists of ASD-associated genes from each dataset were functionally
annotated and analysed to identify common canonical pathways. The integration of such
heterogeneous datasets aimed to highlight canonical pathways that are dysregulated across a
range of molecular datasets from different cohorts, tissue types and ages, which could indicate
common underlying mechanisms in ASD.
The gene list from each study was converted into NCBI Entrez IDs using a combina-
tion of gene ID conversion tools, namely (i) Database for Annotation, Visualization and
Integrated Discovery (DAVID) v6.8 Gene Accession Conversion Tool (https://david.ncifcrf.
gov/conversion.jsp. Accessed on 8 March 2021) [31,32], (ii) the g:Profiler tool g:convert for
Gene ID conversion (https://biit.cs.ut.ee/gprofiler/convert. Accessed on 8 March 2021) [33],
(iii) the GIDcon batchwise gene ID conversion tool (http://resource.ibab.ac.in/GIDCON/
geneid/home.html. Accessed on 8 March 2021) and (iv) the SYNGO geneset analysis tool
(https://syngoportal.org/convert.html. Accessed on 8 March 2021). For the datasets written
as Ensemble Gene IDs, the Ensemble ID History Converter (https://www.ensembl.org/
Homo_sapiens/Tools/IDMapper. Accessed on 8 March 2021) was used to map all identifiers
to matched identifiers in the most recent release of the database. Subsequently, all Ensemble
Identifiers, Gene Symbols or GenBank accession numbers not identified through any of these
ID conversion tools were manually submitted to NCBI (https://www.ncbi.nlm.nih.gov/gene.
Accessed on 8 March 2021) to find the corresponding Gene ID. Deprecated Ensemble IDs that
were not matched to an ID in the most recent release were excluded.
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Table 1. A description of the 19 datasets included in this review, summarizing the type of study, the cohort size, the tissue type,
and the definition of the final dataset used from each study. DE = differentially expressed; DM = differentially methylated.
Proteomics Analysis
Shen et al., 2019 [11] 41 DE proteins in ASD 24 male and 6 female ASD (2–6 yrs) andage/gender-matched controls
Blood
Blood PBMCs
Hewitson et al., 2021 [14] 86 downregulated, 52 upregulatedproteins in ASD (FDR < 0.05)
76 ASD (boys) and 78 controls (boys), 18 months
to 8 yrs Blood serum
Shen et al., 2018 [15] 24 DE proteins in ASD 24 male and 6 female autistic patients (2–6 yrs) andage/gender-matched controls Blood plasma
Yang et al., 2018 [16] Eight biomarker peaks with higherexpression in ASD
Han Chinese children: 68 ASD (average age = 12.4 yrs)
and 80 age-matched controls (average age 14.3 yrs) Blood serum
Yao et al., 2021 [17]
59 genes predicted to encode
ASD-related blood-secretory
proteins; six proteins were
validated using an ELISA
79 brain tissue samples from 19 ASD and 17 controls;
ELISA analysis of 20 ASD, and 20
age/gender-matched controls. The average age of the
patients and controls were 24 yrs (ranged from 2 to 56)




Abraham et al., 2019 [18]
146 DE proteins from BA19
between ASD and controls
(p < 0.05)
9 ASD cases (2–60 yrs) and 9 age- and gender-matched
controls (1–60 yrs)
Cerebellum (CB) and
Brodmann area 19 (BA19)
Transcriptomic Meta-Analysis
Reference Dataset Used in Analysis Cohort Tissue
Tylee et al., 2017 [19] 90 DE genes in ASD (p < 0.05) 626 ASD and 447 controls across seven independentstudies; mean age and SD of 5 ± 3.8 yrs
Blood
Ex vivo peripheral blood
samples or isolated leukocyte
samples derived from
peripheral blood
Mordaunt et al., 2019 [20] 172 DE genes in ASD (p < 0.01) 59 ASD, 92 non-typically developing, 120 typicallydeveloping controls
Umbilical cord blood samples
from both the Markers of
Autism Risk in
Babies-Learning Early Signs




Gao et al., 2020 [21] 3624 DE genes in ASD 96 ASD and 42 controls age range: 2–18 yrs Peripheral blood samples(GSE18123 and GSE6575)
He et al., 2019 [22] DE genes (p < 0.05) in ASD 485 ASD and 398 controls





He et al., 2019 [22] DE genes (p < 0.05) in ASD 109 ASD and 129 controls
Brain
tissue




Forés-Martos et al., 2019 [23] 1055 DE genes in ASD(FDR p < 0.05)
34 ASD cases and 130 controls across three studies.
Mean age 20.3 yrs Frontal cortex tissue
Rahman et al., 2020 [24] 1567 DE genes in ASD 15 ASD and 15 controls across two studies Post-mortem brain tissue(GSE30573 and GSE64018)
Wright et al., 2017 [25]
1463 DE genes in ASD across all
moderately expressed Ensembl
genes (13,011) at marginal
statistical (p < 0.05) significance
13 ASD (3F, 10M), average age 22 yrs (4 to 67) and 39
controls (9F, 30M), average age 22 yrs (2 to 69)
Postmortem brain tissue:
dorsolateral prefrontal cortex
Yao et al., 2021 [17] 364 DE genes in ASD
79 brain tissue samples from 19 ASD and 17 controls.
Average age of the patients and controls were 24 yrs (2
to 56) and 34.6 yrs (16 to 56) respectively
Brain tissue: cerebellum,
frontal cortex, and temporal
cortex (GSE28521)
Ramaswami et al., 2020 [26] 5200 DE genes (FDR < 0.05)
82 ASD samples and 74 control samples from 47 ASD
and 44 control brains from (Parikshak et al.); mean age
and SD were 28 (+/−17) yrs
Frontal and temporal cortex
tissue from the Harvard
Autism Tissue Program and
NIH Neuro Brain Bank
DNA Methylation Analysis
Mordaunt et al., 2020 [27] 537 DM genes in both discoveryand replication sets in males
Discovery set = 74 males (35 ASD and 39 controls) and
32 females (15 ASD and 17 controls) in the MARBLES
and EARLI studies. Replication set = 38 males (21 ASD
and 17 controls) and 8 females (5 ASD and 3 controls)
Blood
Umbilical cord blood samples
Hu et al., 2020 [28]
181 DM genes that overlap
between the discovery and
validation groups MALES
21 ASD and 21 controls, average age 8.4 yrs LCLs
Wong et al., 2019 [29]
i)Top ranked iASD-associated DM
probes identified in the
cross-cortex model incorporating
both prefrontal cortex and
temporal cortex data
43 ASD and 38 controls, average age at death 29.0
(+/−18.9) and 48.7 (+/−8.8) yrs respectively
Brain
tissue
Post-mortem brain tissue from
prefrontal cortex, temporal
cortex and cerebellum
Ramaswami et al., 2020 [26] DM genes (promoter or gene body;FDR < 0.05)
56 ASD samples and 41 control samples from 33 ASD
and 26 control brains. Mean age
and SD = 34 (+/−15) yrs
Frontal and temporal cortex
tissue from the Harvard
Autism Tissue Program and
NIH Neuro Brain Bank
Stathopoulous et al., 2020 [30] 898 DM genes in ASD 48 boys (32 ASD and 16 controls, 6–12 yrs) Buccalcells Buccal DNA
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Subsequently, each gene list was subjected to gene set enrichment analysis [GSEA]
against the Molecular Signatures Database (MSigDB) [34], using the open-source GSEA
tool developed by UC San Diego and the Broad Institute (http://www.gsea-msigdb.org/
gsea/msigdb/annotate.jsp. Accessed on 12 April 2021) [35,36]. Each dataset was annotated
with respect to the top 10 significantly enriched Hallmark Canonical pathways where
each pathway represents a well-defined biological process in one curated gene set [37].
These enrichment signatures were compared between independent datasets to identify
canonical pathways that were consistently dysregulated in ASD at all three molecular
levels: proteomic, transcriptomic and epigenomic.
The proteomic datasets were examined to identify a subset of differentially expressed
proteins that were also implicated in transcriptomic and DNAm data in ASD. After con-
version to NCBI Entrez gene IDs, this subset of proteins was annotated with respect
to significantly enriched Hallmark canonical pathways, ClinVar disease pathways and
transcription factor protein–protein interactions (TF-PPIs) using the Enrichr gene list anal-
ysis tool suite (https://maayanlab.cloud/Enrichr/. Accessed on 12 April 2021) [38,39].
TF-PPIs are defined by a library of datasets corresponding to a list of transcription fac-
tors and the proteins that interact with them. The top 10 significantly enriched TF-PPIs
were used to generate a signalling network based on the SIGnaling Network Open Re-
source (SIGNOR) v2.0 database [40], using the Network Analyst web interface (https:
//www.networkanalyst.ca/NetworkAnalyst/home.xhtml. Accessed on 12 April 2021) [41].
This network was used to explore the relationship between the canonical pathways impli-
cated in ASD, biological processes and phenotypic aspects of ASD aetiology.
3. Results
After collating the data from 19 different studies (Table 1), we determined the top 10
significantly enriched Hallmark canonical pathways for each of the datasets (Figure S1).
These enrichment signatures were compared across all 19 datasets to identify canonical
pathways that were consistently supported by all three molecular approaches (Table 2).
Eight Hallmark canonical pathways were enriched in seven or more different datasets
(Figure 1). Of these, six canonical pathways were supported using all three molecular
approaches, with five of these pathways shown to be dysregulated in brain tissue using
all three molecular approaches (Supplementary Figure S2). These were the pathways for
oxidative phosphorylation, mTORC1 signalling, coagulation, xenobiotic metabolism and
adipogenesis. Notably, three canonical pathways—oxidative phosphorylation, mTORC1
signalling and xenobiotic metabolism- were each implicated in at least three proteomic,
three transcriptomic and two DNA methylation studies. The oxidative phosphorylation
and mTORC1 signalling pathways were the two pathways that were most frequently
associated with ASD. These two pathways were each implicated in 10 different datasets
and these datasets included proteomic, transcriptomic and DNAm datasets derived from
post-mortem brain tissue from individuals with ASD. While post-mortem brain tissue does
not always reflect disease mechanisms that are relevant during neurodevelopment and early
childhood, it is important to note that both the mTORC1 and oxidative phosphorylation
pathways were also implicated in enrichment signatures from cohorts of younger children.
Specifically, both pathways were implicated in blood proteomic profiles in children ranging
from 18 months to 8 years [14], frontal cortex transcriptomic signatures from cohorts where
the mean age was between 20.3–28 years [23,26] as well as DNAm data from children
between 6–12 years [30].
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Table 2. A summary of the Hallmark Enrichment Signatures of 19 ASD molecular datasets, highlighting canonical pathways that
were most consistently implicated in ASD proteomic, transcriptomic, and DNAm datasets from blood and brain tissue. Each
independent dataset was annotated with respect to the top ten significantly enriched Hallmark canonical pathways (FDR < 0.5);
data indicate the number of enrichment signatures implicating each canonical pathway. Pathways in bold = strongly supported
using all three molecular approaches; pathways in italicised = supported by two (of three) molecular datasets.
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OXIDATIVE PHOS-
PHORYLATION 0/2/1
COMPLEMENT 3/0 COMPLEMENT 4/4 P53 PATHWAY 1/1/1
OXIDATIVE
PHOSPHORYLATION 1/2 MTORC1 SIGNALING 3/3 MITOTIC SPINDLE 1/1/1




















RESPONSE 3/4 E2F TARGETS 0/1/1
MYC TARGETS V1 1/1 APOPTOSIS 3/4 DNA REPAIR 0/1/1





KRAS SIGNALING UP 0/4
The four additional canonical pathways that were consistently implicated across
molecular datasets were the xenobiotic metabolism, p53, adipogenesis and coagulation
pathways. Both the xenobiotic metabolism and adipogenesis pathways were implicated in
enrichment signatures from brain tissue using all three molecular approaches and were also
implicated in studies of younger children using proteomic [14,15], transcriptomic [20,26]
and DNAm approaches [26,27,30]. While the p53 pathway was not implicated in pro-
teomic data from brain tissue, five transcriptomic datasets from brain tissue were enriched
for p53 signalling [22,23,25,26] as well as three DNAm screens from blood, brain, and
buccal tissue [26,28,30].
It is important to note that four of six proteomic datasets included in this review
are blood-based datasets, which means that they provide limited insight into which pro-
teins might be differentially expressed in the brain. Therefore, this review compared the
canonical pathways implicated in blood-based proteomic profiles with those enriched in
proteomic, transcriptomic and DNAm data from brain tissue in order to highlight canonical
pathways that could have functional implications in ASD. The coagulation pathway was
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the canonical pathway that was most consistently enriched in the ASD proteomic data.
This pathway was implicated in five out of six proteomic datasets, including three datasets
derived from blood samples in children between 18 months and 15 years [14–16] as well as
post-mortem brain tissue from BA19 and the cerebellum [18]. The coagulation pathway
was also enriched in both transcriptomic and DNAm datasets derived from umbilical
cord blood [20,27], as well as transcriptomic data from brain tissue in individuals between
24 and 36 years old [17]. The complement pathway, which is a related component of
the innate and adaptive immune response pathways, was implicated in three proteomic
profiles in blood, and was also dysregulated in three transcriptomic studies in ASD brain
tissue [23–25]. In addition, the allograft rejection pathway, which can be induced by com-
plement activation, was enriched in blood based proteomic profiles [11] and transcriptomic
data from blood [19,22] and brain tissue [22,24].




Figure 1. Hallmark canonical pathways most consistently implicated in ASD molecular data. Datasets were collated from 
19 studies and meta-analyses on ASD papers published between 2017 and 2021: six proteomic, eight transcriptomic and 
six DNA methylation (DNAm) studies. All gene lists were converted into NCBI Entrez gene IDs. Each dataset was 
annotated with respect to the top 10 significantly enriched Hallmark canonical pathways. The Hallmark canonical 
pathways that were significantly enriched in seven or more independent ASD proteomic, transcriptomic and DNAm 
datasets are shown; those shown in bold are those consistently implicated using all three molecular approaches. 
We also used a second approach to explore how the proteomic data articulated with 
the transcriptomic and DNAm data associated with ASD. We identified a subset of 121 
proteins that were implicated in ASD using all three molecular approaches (Figure S3; 
Supplementary Table S2). Of these proteins, 53 were shown to be altered in ASD brain 
tissue using all three molecular methods. Of the proteins that were differentially 
expressed in blood, 10 were also implicated in transcriptomic and DNAm data in brain 
tissue; 12 were dysregulated in brain transcriptomic profiles and 25 were supported by 
DNAm studies in brain tissue. The remaining 21 proteins were shown to be altered in 
blood using proteomic, transcriptomic and DNAm screens. We characterised the dataset 
of all 121 differentially expressed proteins that were supported by transcriptomic and 
DNAm data with respect to enriched Hallmark canonical pathways, disease phenotype 
pathways, and downstream biological processes in order to explore the functional 
implications associated with these proteins. This subset of proteins was significantly 
enriched for Hallmark canonical pathways involved in mTOR signalling (this includes 
mTORC1 signalling and PI3K-AKT-mTOR signalling), metabolism (this includes 
oxidative phosphorylation, glycolysis, fatty acid metabolism and adipogenesis), and 
immune responses (this includes complement, allograft rejection and IL6-JAK-STAT3 
signalling) (Supplementary Table S3). The 10 most significantly enriched Hallmark 
canonical pathways in this subset of proteins included four canonical pathways that were 
also consistently enriched across all 19 datasets: mTORC1 signalling, oxidative 
phosphorylation, adipogenesis and the complement response (Figure 2A). Together, the 
four canonical pathways highlighted in both analyses converge on signalling networks 
that regulate neural stem cell proliferation, differentiation, metabolism, redox 
homeostasis, and reactive gliosis during neurodevelopment (Figure 2B). 
The subset of 121 proteins that were implicated using all three molecular approaches 
was also enriched for five ClinVar disease pathways associated with neurological, 
Figure 1. Hallmark canonical pathways most consistently implicated in ASD molecular data. Datasets were collated from
19 studies and eta-analyses on ASD papers published between 2017 and 2021: six proteomic, eight transcriptomic and six
DNA methylation (DNAm) studies. All gene lists were converted into NCBI Entrez gene IDs. Each dataset was annotated
with respect to the top 10 significantly enriched Hallmark canonical pathways. The Hallmark canonical pathways that were
significantly enriched in seven or more independent ASD proteomic, transcriptomic and DNAm datasets are shown; those
shown in bold are those consistently implicated using all three molecular approaches.
We also used a second approach to explore how the proteomic data articulated with the
transcriptomic and DNAm data associated with ASD. We identified a subset of 121 proteins
that were implicated in ASD using all three molecular approaches (Figure S3; Supple-
mentary Table S2). Of these proteins, 53 were shown to be altered in ASD brain tissue
using all three molecular methods. Of the proteins that were differentially expressed
in blood, 10 were also implicated in transcriptomic and DNAm data in brain tissue; 12
were dysregulated in brain transcriptomic profiles and 25 were supported by DNAm
studies in brain tissue. The remaining 21 proteins were shown to be altered in blood using
proteomic, transcriptomic and DNAm screens. We characterised the dataset of all 121
differentially expressed proteins that were supported by transcriptomic and DNAm data
with respect to enriched Hallmark canonical pathways, disease phenotype pathways, and
downstream biological processes in order to explore the functional implications associ-
ated with these proteins. This subset of proteins was significantly enriched for Hallmark
canonical pathways involved in mTOR signalling (this includes mTORC1 signalling and
PI3K-AKT-mTOR signalling), metabolism (this includes oxidative phosphorylation, gly-
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colysis, fatty acid metabolism and adipogenesis), and immune responses (this includes
complement, allograft rejection and IL6-JAK-STAT3 signalling) (Supplementary Table S3).
The 10 most significantly enriched Hallmark canonical pathways in this subset of proteins
included four canonical pathways that were also consistently enriched across all 19 datasets:
mTORC1 signalling, oxidative phosphorylation, adipogenesis and the complement re-
sponse (Figure 2A). Together, the four canonical pathways highlighted in both analyses
converge on signalling networks that regulate neural stem cell proliferation, differentiation,
metabolism, redox homeostasis, and reactive gliosis during neurodevelopment (Figure 2B).




Figure 2. ASD proteomic profiles converge on four canonical pathways involved in mitochondrial metabolism, 
neurogenesis and neuroinflammation. (A) The Venn diagram shows the Hallmark canonical pathways implicated in seven 
or more independent datasets (in blue), the enriched canonical pathways in the 121 differentially expressed proteins 
implicated in transcriptomic and DNAm datasets (light grey) and the pathways that overlap (in bold font). (B) The four 
pathways implicated in both analyses (Figure 2A) converge on the regulation of the following biological processes (in 
blue): neural stem cell proliferation, neurogenesis, mitochondrial metabolism, and inflammation. The mTORC1 signalling 
pathway induces oxidative phosphorylation via the activation of camp-responsive element binding protein 1 (CREB1) and 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A), which regulates mitochondrial 
metabolism and the antioxidant response. PPARGC1A is regulated by peroxisome proliferator-activated receptor gamma 
(PPARGy), which acts as a master regulator of lipid metabolism and is essential to induce adipogenesis. Adipogenesis is 
negatively regulated by WNT signalling, which inhibits PPARGy, PPARGC1A and mTORC1 signalling to regulate stem 
cell proliferation and differentiation. Mitochondrial metabolism regulates metabolic and redox homeostasis which 
governs the inflammatory profile of microglia. Oxidative stress leads to the over proliferation of reactive microglia, which 
triggers the pro-inflammatory complement response. 
 
Figure 2. ASD proteomic profiles converge on four can nical pathways involved i mitocho drial metabolism, neurogenesis
and neuroi flammation. (A) The Ve n diagram shows the Hallmark canonical pathw ys implicated in s ve or more
independent datasets (in blue), the enriched canonical pathways in the 121 differentially expressed proteins implicated
in transcriptomic and DNAm datasets (light grey) and the pathways that overlap (in bold font). (B) The four pathways
implicated in both analyses (Figure 2A) converge on the regulation of the following biological processes (in blue): neural
stem cell proliferation, neurogenesis, mitochondrial metabolism, and inflammation. The mTORC1 signalling pathway
induces oxidative phosphorylation via the activation of camp-responsive element binding protein 1 (CREB1) and peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A), which regu ates mito hondrial metabolis nd
the antioxidant response. PPARGC1A is regulated by peroxiso e proliferator-activated receptor gamma (PPARGy), which
acts as a master regulator of lipid metabolism and is essential to induce adipogenesis. Adipogenesis is negatively regulated
by WNT signalling, which inhibits PPARGy, PPARGC1A and mTORC1 signalling to regulate stem cell proliferation and
differentiation. Mitochondrial metabolism regulates metabolic and redox homeostasis which governs the inflammatory
profile of microglia. Oxidative stress leads to the over proliferation of reactive microglia, which triggers the pro-inflammatory
complement response.
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The subset of 121 proteins that were implicated using all three molecular approaches
was also enriched for five ClinVar disease pathways associated with neurological, immuno-
logical, and metabolic diseases (Table 3). Notably, the most significantly enriched disease
pathway was for Leigh syndrome, which is a paediatric mitochondrial disease that mani-
fests with severe neuropathology [42]. Therefore, the above-mentioned proteins converge
on three central components of ASD pathophysiology which may yield insight into the link
between canonical pathways and the dysregulation of biological processes in ASD aetiology.
Consequently, we examined the protein–protein interaction networks and downstream
signalling pathways associated with this dataset by testing for significant enrichment
of TF-PPIs. The top 10 significantly enriched TF-PPIs are key transcriptional regulators
of mitochondrial metabolism (CREBP1A, PPARGC1A and HNF1A), lipid metabolism
(PPARCG1A and STAT1), adipogenesis (NR3C1), the p53 pathway (TP53; TP63) and inflam-
mation (NR3C1, STAT1) (Supplementary Table S4). Notably, several of these transcription
factors mediate signalling via the PI3K–AKT–mTOR (HTT, TP53, CREBP1A, PPARGC1A)
or ERK–mTOR (ESR1, STAT1, HNF1A) pathways. This highlights some of the transcription
factors that regulate the canonical pathways implicated in ASD molecular data. The sig-
nalling network between the top 10 significantly enriched transcription factors converged
on two SIGNOR stimuli (ROS and DNA damage), as well as six SIGNOR signalling path-
ways, namely; polarization, proliferation, apoptosis, cell death, mitochondrial biogenesis,
and inflammation (Figure 3). Therefore, this subset of differentially expressed proteins
highlights a link between signalling pathways, biological processes and ClinVar disease
phenotypes associated with ASD aetiology. Altogether, recent proteomic profiling studies,
in conjunction with previously published transcriptomic and epigenomic meta-analyses,
consistently implicate canonical pathways involved in neuronal metabolism, differentiation
and inflammation.
Table 3. ClinVar disease pathways that are significantly enriched in the 121 differentially expressed
proteins that are also implicated in both transcriptomic and DNAm datasets.
ClinVar Disease Pathway Disease Phenotype p Value




Pyruvate Dehydrogenase Complex Deficiency 0.0299
Mitochondrial DNA Deletion Syndrome 0.0474
Autoimmune Lymphoproliferative Syndrome Autoimmune disease 0.0358
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proteomic studies are able to detect different protein isoforms or post-translational 
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Figure 3. Signalling network between the top 10 transcription factor protein–protein interactions (PPI) enriched in the
set of 121 proteins that are supported by ASD proteomic, transcriptomic, and epigenomic datasets. This PPI network
was annotated with respect to signalling pathways in the SIGnaling Network Open es rce (SI ) 2.0 database of
manually an otated causal relationships betwe n proteins that participate in signal transduction.
4. iscussion
olecular research of ASD requires a “multi-omics” approach to comprehensively
characterise the convergent biological processes associated with its complex genetic archi-
tecture. Proteomic, transcriptomic, and epigenomic approaches are well-established as
ways to investigate changes in gene regulation, expression, and function in ASD. DNA
ethylation is widely recognized as an epigenetic regulator of gene expression that con-
tributes to ASD aetiology [43]. Transcriptomic studies facilitate an understanding of the
link between the genetic mutations associated with ASD and changes in gene expression
and function [11]. Recent advances in high-throughput proteomic technologies have con-
tributed towards the progress of ASD proteomic profiling studies using both peripheral
and brain tissue to provide insight into the cellular mechanisms involved in ASD aeti-
ology. Proteomic approaches come with a unique set of advantages and limitations in
the context of ASD research. In contrast to other molecular methods, proteomic studies
are able to detect different protein isoforms or post-translational modifications and have
the potential to identify disease biomarkers and drug targets for the diagnosis and treat-
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ment of ASD [9,11]. One major challenge associated with the identification of proteomic
biomarkers in ASD is the scarcity of brain tissue available for research, coupled with the
fact that brain tissue is generally inaccessible as the tissue of choice for diagnosis. Recent
reviews of ASD proteomic data highlight the utility of blood-based proteomic biomarkers
in ASD; the proteomic expression profiles of peripheral tissues have been shown to cor-
relate moderately with those of brain tissue, and blood samples are more easily accessed
and less invasive to obtain for diagnostic purposes [11]. Additionally, novel bioinformatic
approaches have been used to predict ASD-associated blood secretory proteins; and this
approach has recently been experimentally validated in an ASD cohort [17]. Nevertheless,
the variation in protein expression between different tissue types remains an important
consideration for the analysis of proteomic datasets. This is compounded by the fact that
protein expression can also vary widely between different brain regions, which means that
even brain-based proteomic profiles only provide limited insight into disease mechanisms.
This highlights how the aetiological complexity of ASD is compounded by the hetero-
geneity between molecular datasets derived from different tissue types, brain regions and
molecular methods.
Despite these limitations, proteomics can be an essential component of a multi-omic
molecular approach to ASD aetiology. Protein expression studies can be used to investigate
biologically relevant protein interaction networks and signalling pathways [18] and can
yield insight into the link between molecular and phenotypic aspects of disease aetiology.
The approach taken in this review considers both the strengths and limitations of ASD
proteomics research. Our review includes proteomics data from both the cortex (BA19) and
cerebellum, and we cross-reference these datasets against transcriptomic and DNAm data
from predominantly the prefrontal cortex and temporal cortex. These brain regions are
relevant in the context of ASD because previous studies have found that ASD-associated
changes in mRNA expression, miRNA expression, DNA methylation, and histone acetyla-
tion were predominantly localized to the cerebral cortex [26]. This review integrated the
functional annotations of ASD proteomic, transcriptomic and DNAm datasets from both
blood and brain tissue to identify common canonical pathways associated with ASD.
We found that the canonical pathways involved in metabolism, redox homeostasis,
inflammation and proliferation are consistently supported by proteomic, transcriptomic
and DNAm data in ASD (Figures 1 and 2). This review explored the link between canonical
pathways, biological processes and disease phenotype pathways in ASD by function-
ally annotating a subset of differentially expressed proteins that were also supported by
transcriptomic and DNAm data. This subset of proteins was enriched for four canonical
pathways that were also implicated in seven or more independent datasets. These were
the pathways for oxidative phosphorylation, mTORC1 signalling, adipogenesis and the
complement response (Figure 2A). Additionally, the other six most significantly enriched
Hallmark pathways in this subset of proteins also converge on biological processes impli-
cated across all 19 independent datasets. Both the oestrogen response and PI3K-AKT-MTOR
pathways converge on mTORC1 signalling, while the allograft rejection response has been
highlighted as a component of the complement cascade, and fatty acid metabolism and
glycolysis share common upstream regulators with adipogenesis and oxidative phosphory-
lation. The ten most significantly enriched TF-PPIs in this subset of proteins highlighted
key transcriptional regulators of these canonical pathways. These transcriptional regulators
form a signalling network that highlights how these canonical pathways regulate biological
processes involved in neuropathology (Figure 3). This network converges on the SIGNOR
pathways for mitochondrial biogenesis and inflammation, and this is consistent with prior
evidence linking mitochondrial dysfunction [44–49] and neuroinflammation [50–52] to
ASD. The polarization and proliferation pathways are essential regulators of neural stem
cell self-renewal and differentiation [53–55], while the apoptosis and cell death signalling
pathways are implicated as mechanisms whereby microglia drive synaptic pruning, and
the maturation and migration of neuronal progenitors [56]. In addition, this subset of
proteins was significantly enriched for five ClinVar disease pathways associated with
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neuropathology, mitochondrial dysfunction or auto-immune disease (Table 3). Therefore,
the differentially expressed proteins highlighted in this review are linked to both molecular
and phenotypic facets of ASD aetiology.
The common canonical pathways highlighted above are each established as molecular
mechanisms contributing to ASD aetiology. In addition, in vitro and in vivo model systems
have demonstrated that these pathways play an essential role in the regulation of neurode-
velopment, and converge on a link between mitochondrial dysfunction, neurogenesis, and
inflammation. Notably, the functional enrichment signatures of most of the ASD omics
datasets included in this review are not representative of early embryogenesis, due to
the challenges associated with accessing relevant tissue samples or databanks. Therefore,
the datasets included in this review provide limited insight into the mechanisms that
might be dysregulated during neurodevelopment. However, this review highlights canon-
ical pathways that are dysregulated in functional enrichment signatures obtained using
three different molecular approaches from a wide range of tissue types and individuals
of different ages. Therefore, these common pathways may point to common underlying
mechanisms in ASD, which has potential relevance in the context of neurodevelopment.
While this discussion does not aim to demonstrate a direct link between these molecular
mechanisms and disease aetiology, it is useful to consider how the canonical pathways
implicated in this review are established as aspects of ASD aetiology, and to review the
implications of the dysregulation of these pathways during neurodevelopment.
Firstly, a role for mTORC1 signalling is well described in ASD [57,58]. Mutations in
tuberous sclerosis complex (TSC) and phosphatase and tensin homolog (PTEN), which are
both central regulators of mTORC1 signalling, are associated with autistic behaviours [59–61].
Aberrant mTOR signalling is associated with altered synaptogenesis and ASD-like neu-
rophysiology in animal and organoid model systems [62–67]. Moreover, the mTOR sig-
nalling pathway is a promising therapeutic target in ASD [68]. The canonical pathways
for mTORC1 signalling and oxidative phosphorylation were the two most commonly
implicated pathways in our analyses which is consistent with evidence showing that mito-
chondrial dysfunction is involved in ASD aetiology [44–49]. Mitochondrial function has
recently been proposed as a central driver of neuronal differentiation [69–72] and the tight
coregulation of mTORC1 signalling and mitochondrial metabolism is essential to control
neurogenesis. The transition from undifferentiated neuronal stem cells (NSCs) to mature
neurons relies on a metabolic shift from aerobic glycolysis to mitochondrial respiration. The
latter fuels neuronal migration, dendrite formation and synaptogenesis [73]. The mTOR
signalling pathway plays a central role in driving this metabolic switch, which is essential
for neuronal survival and differentiation [71]. Neurogenic factors induce AKT-MTORC1
signalling, which upregulates peroxisome proliferator-activated receptor-gamma coacti-
vator (PPARGC1A) signalling to induce mitochondrial respiration and biogenesis [70,74].
Conversely, cellular metabolism regulates mTOR signalling via the AMP-dependent pro-
tein kinase (AMPK), which is inhibited by a decrease in the AMP:ATP ratio [75]. The
dysregulation of signalling between mTORC1 and mitochondrial metabolism during de-
velopment has profound consequences for NSC commitment and differentiation, and the
development and maintenance of mature neuronal networks.
We also observed a consistent enrichment of the adipogenesis pathway in ASD molecu-
lar data, which implicates the same networks that regulate stem cell metabolism and differ-
entiation. Adipogenesis is regulated by the “opposite interplay” between WNT/B-catenin
signalling and peroxisome proliferator-activated receptor gamma (PPARGy), each of which
negatively regulates the other [76]. WNT signalling is directly involved in regulating NSC
maintenance, proliferation, and differentiation [77,78] and WNT responsive genes maintain
aerobic glycolysis in NSCs [71]. This highlights that the WNT pathway is at the intersection
between stem cell metabolism and development. Crosstalk between WNT signalling and
mTORC1 signalling is linked to the “Warburg effect” that induces aerobic glycolysis and
over-proliferation in cancer cells [76]. A dysregulation of these same pathways during
neurodevelopment could disrupt NSC commitment and differentiation. In fact, chronic
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activation of WNT signalling altered mTOR signalling in human organoids, leading to
increased NSC proliferation, impaired neuronal differentiation and disrupted radial glial
organization [79]. Moreover, in vivo downregulation of WNT signalling leads to premature
neurogenesis and atypical behaviours [80]. The WNT/B catenin pathway has also been
implicated in ASD genetic and transcriptomic data [81–85].
On the other hand, PPARGy acts as a master regulator of lipid metabolism and
regulates target genes necessary for differentiation, fatty acid transport, carbohydrate
metabolism, and energy homeostasis [86]. Mitochondrial fatty acid oxidation (FAO) is
essential for the self-renewal of NSCs, but fatty acid metabolism shifts towards lipogenesis
during neurogenesis [87–90]. In vitro studies show that this shift in fatty acid metabolism
is regulated by the AMPK-PPARGC1A axis [90]. The coregulation between PPARGy and
PPARGC1A means that glucose and fatty acid metabolism are intrinsically linked during
neurodevelopment. Disrupting FAO inhibits stem cell self-renewal [88,89] and impairs
NSC differentiation in mouse models [91]. Recent reviews of ASD proteomic data also find
that proteins involved in lipid metabolism are differentially expressed in ASD [92,93]. A
role for PPARGy is supported by increasing evidence of mitochondrial FAO deficiencies
in ASD, and PPARGy agonists have been proposed as therapeutic agents in ASD [94,95].
This highlights how PPARGy is implicated in neurodevelopment and ASD, and how the
canonical pathways for mTORC1 signalling, oxidative phosphorylation and adipogenesis
converge on the signalling between neuronal metabolism and differentiation.
A dysregulation of the signalling between mitochondrial metabolism and neurogene-
sis has significant implications for neuronal development and function. Firstly, mitochon-
drial oxidative phosphorylation is one of the primary producers of intracellular reactive
oxygen species (ROS) and disruptions to mitochondrial metabolism can lead to oxidative
stress [96]. Increased oxidative stress is a well-documented aspect of ASD pathophysiol-
ogy; the evidence for markers of oxidative stress associated with glutathione metabolism,
lipid peroxidation, protein oxidation, DNA oxidation and antioxidant enzyme activity
has been comprehensively reviewed in recent years [45,97–102]. In the context of neu-
rodevelopment, this has significant implications for the redox regulation of neurogenesis.
Undifferentiated NSCs are characterized by high levels of endogenous ROS, which plays a
functional role in stem cell maintenance [103,104] and oxidative stress is known to promote
NSC self-renewal and inhibit downstream neurogenesis [96,104]. Studies on in vitro and
in vivo model systems consistently demonstrate that increasing oxidative stress [105–107]
or disrupting mitochondrial homeostasis and function [108–111] leads to an inhibition of
neurogenesis and a shift towards gliosis; the latter is associated with neuroinflammation
and is established as a hallmark of ASD aetiology. Clinical studies also report that gliosis is
one of the neuropathological manifestations of mitochondrial disease [43,112–115].
Many of the canonical pathways highlighted in this review are implicated as mecha-
nisms involved in the response to oxidative stress and gliosis during neurogenesis. Clinical
data has reported mTOR signalling as a mechanism that connects mitochondrial disease to
gliosis [116], with both in vitro [117], and in vivo, studies [118] showing that gliosis can be
induced by targeted disruptions to mTOR signalling. Crosstalk between the PPARGy and
WNT canonical pathways is also associated with increased oxidative stress and chronic
inflammation in cancer [119], and WNT/B-catenin-PPARGy signalling can be targeted to re-
duce reactive gliosis in models of neurodegenerative disease [120–122]. In addition, the p53
pathway and xenobiotic metabolism were each implicated in eight or more independent
datasets in our analysis and these pathways were supported by all three types of molecular
data (Figure 1). The p53 signalling pathway is a central regulator of inflammation, oxida-
tive stress, and apoptosis [123], while the canonical pathway for xenobiotic metabolism is
composed of genes that respond to inflammation, metabolic stress, and ROS [124]. Notably,
both mTOR and WNT signalling regulate p53 degradation [73,125,126]. The p53 signalling
pathway also plays an important role in neural precursor cell self-renewal, neuronal com-
mitment, and reactive gliosis in response to mitochondrial dysfunction [110,111,127].
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Gliosis is characterized by highly reactive microglia and astrocytes, leading to an
overproduction of glial-specific fibrillary acidic protein (GFAP) and inflammatory cy-
tokines [128]. This review highlights the consistent enrichment of inflammatory canon-
ical pathways in ASD transcriptomic and proteomic data. The canonical pathways in-
volved in inflammatory immune response pathways were those most frequently associated
with the transcriptomic enrichment signatures: six of ten hallmark canonical pathways
that were implicated in at least five independent transcriptomic datasets were related
to immune responses. This is consistent with a substantial body of work implicating
neuroinflammation and gliosis as mechanisms of pathology of ASD, which has been thor-
oughly reviewed elsewhere [50–52,129–132]. A role for inflammation, astrocyte function
and microglial activation is well-supported by transcriptomic and proteomic studies in
ASD brain tissue [133–135]. This is also consistent with immunohistochemistry, positron
emission tomography and morphological data in ASD [129,136,137]. Notably, microglial
phagocytosis is responsible for the degradation of proliferating NSCs during neurodevel-
opment [57]. This is essential for synaptogenesis and post-natal synaptic pruning, both
of which are thought to be dysregulated in ASD [129,138,139]. Importantly, microglial
metabolism is closely linked to neuroinflammatory states [140,141], and both glucose and
lipid metabolism regulate microglial activation [142–145]. The dysregulation of glial and
microglial metabolism, proliferation and function can alter neuronal differentiation, im-
pair synaptogenesis and pruning, and change neuroinflammatory states, with profound
implications for neural architecture and connectivity [146].
Our analysis of recent ASD proteomic profiles further supports a role for neuroin-
flammation in ASD. The complement and coagulation cascades were implicated in three
and five out of six ASD proteomic studies respectively, which is supported in independent
reviews of ASD proteomic data [13,92,93]. Both cascades form part of the innate immune
system and interactions between them via mannose-binding lectin-associated serine pro-
teases are well documented [147–152]. Both cascades are involved in the inflammatory
response by reactive microglia [153,154]. Coagulation proteins affect the morphology, pro-
liferation, and function of astrocytes [153], while the complement system is implicated as a
mechanism by which microglia regulate neurogenesis, neuronal migration and synaptic
pruning [154–157]. Complement proteins play a role in microglial activation, which can
influence neuroinflammatory signalling and neurodevelopment [158]. Animal models
show that genetic knockdown of complement proteins impairs neuronal migration, while
activation of the complement system rescues this deficit [155]. There is mounting evidence
for complement system dysfunction in neurodevelopmental disorders [156], which has
been proposed as one of the mechanisms behind the synaptic pruning deficits, increased
dendritic spine density, cortical hyperconnectivity and resultant behavioural phenotypes in
ASD [157]. Therefore, the immune response cascades enriched in ASD proteomic profiles
function as a link between gliosis, neurogenesis, and synaptogenesis, highlighting a point
of convergence between these different mechanisms in ASD pathology.
Collectively, the canonical pathways highlighted in this review are consistent with
known pathways that to contribute to ASD aetiology, as well as pathways that have been
implicated in independent reviews of ASD molecular data. Importantly, our review also
considers the interactions between these canonical pathways, particularly in the context of
neurodevelopment. The latter is often overlooked when the relevance of each canonical
pathway is evaluated in isolation. Previous reviews have comprehensively described the
role of mTORC1 signalling in protein synthesis, neuronal differentiation, migration, and
patterning [57], but these reviews have focused less on the role of mTORC1 as a regulator
of mitochondrial metabolism. The same is true for reviews on the role played by WNT sig-
nalling in neurogenesis and ASD [159,160], which describe the central role played by WNT
signalling in NSC proliferation and differentiation. However, our review emphasises how
WNT-PPARGy signalling intersects with PPARGC1A, anti-inflammatory and antioxidant
responses, and the regulation of mitochondrial biogenesis and metabolism. Given that mi-
tochondrial dysfunction is an established component of ASD aetiology, and that metabolic
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state plays a central role in neuronal differentiation, our review highlights a potentially im-
portant connection between mTORC1, oxidative phosphorylation and neuropathology in
ASD. Finally, our review integrates all of the above with the thoroughly reviewed evidence
for neuroinflammation and oxidative stress in ASD [49–52,97–102] by considering the role
of mitochondrial metabolism in gliosis and microglial activation, and the downstream
consequences for synaptogenesis, neuronal connectivity and behavioural phenotypes.
Therefore, our review is not only consistent with current molecular mechanisms implicated
in ASD, but also highlights an under-explored link between mitochondrial dysfunction,
neuroinflammation and neurodevelopmental pathology.
5. Conclusions
The genetic and phenotypic complexity of ASD makes it challenging to identify the
molecular mechanisms that contribute to its aetiology. Proteomic approaches can yield
novel insight into the dysregulation of biological processes and signalling networks in
ASD. Despite the power of proteomics, there are currently limitations to this approach,
both in terms of sample acquisition, processing, and analysis, and in accurately capturing
variation between different tissue types and developmental stages. In light of these caveats,
we integrated recently published ASD proteomic profiles with large-scale meta-analyses
of whole-genome transcriptomic and DNAm data to compare the functional enrichment
signatures of disparate molecular datasets. Our analysis demonstrates that ASD pro-
teomic, transcriptomic and DNAm data consistently support the dysregulation of mTORC1
signalling, oxidative phosphorylation, adipogenesis and the response to inflammation
and oxidative stress. The mTORC1-, WNT- and PPARGy-signalling pathways are each
well-established regulators of neurodevelopment that are also implicated in ASD and
neurodevelopmental pathology. The mTORC1 signalling pathway regulates oxidative
phosphorylation via PPARGC1A, which operates in concert with PPARGy to regulate
mitochondrial respiration and fatty acid oxidation. These pathways play an essential role
in the tight coupling between stem cell proliferation, differentiation, and mitochondrial
metabolism during neurogenesis. If this coupling is disrupted, this can induce metabolic
and oxidative stress in NSCs. Both metabolic and oxidative stress are known to disrupt
neurogenesis, promote gliosis and induce microglial activation. This proposes a link
between mitochondrial dysfunction, oxidative stress, and gliosis, each of which are well-
established features of ASD aetiology. Given the central role played by glial networks in
neuronal migration and synaptogenesis, gliosis is implicated as a mechanism involved in
neuroinflammation and the neuropathophysiology associated with ASD. In summary, this
review demonstrates that ASD molecular data converges on canonical pathways involved
in mitochondrial function, neurogenesis and neuroinflammation, highlighting how these
three key aspects of ASD aetiology interact, and the relevance of these interactions in the
context of neurodevelopment.
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